Breaking News Instant updates and real-time market news.

STLD

Steel Dynamics

$29.64

(0.00%)

, IGT

International Game

$14.02

(0.00%)

09:40
10/15/19
10/15
09:40
10/15/19
09:40

Unusually active option classes on open October 15th

Unusual total active option classes on open include: Steel Dynamics (STLD), International Game (IGT), JPMorgan (JPM), UnitedHealth (UNH), Goldman Sachs (GS), NVIDIA (NVDA), iShares High Yield Corporate Bond ETF (HYG), Citi (C), Whiting Petroleum (WLL), and Charles Schwab (SCHW).

STLD

Steel Dynamics

$29.64

(0.00%)

IGT

International Game

$14.02

(0.00%)

JPM

JPMorgan

$116.39

(0.00%)

UNH

UnitedHealth

$220.32

(0.00%)

GS

Goldman Sachs

$205.81

(0.00%)

NVDA

Nvidia

$186.51

(0.00%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$86.83

(0.00%)

C

Citi

$70.28

(0.00%)

WLL

Whiting Petroleum

$7.26

(0.00%)

SCHW

Charles Schwab

$37.74

(0.00%)

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 17

    Oct

  • 18

    Oct

  • 27

    Oct

  • 04

    Nov

  • 06

    Nov

  • 12

    Nov

  • 20

    Nov

STLD Steel Dynamics
$29.64

(0.00%)

09/23/19
JPMS
09/23/19
DOWNGRADE
JPMS
Underweight
JPMorgan double downgrades AK Steel, cuts U.S. Steel on flattish price outlook
JPMorgan analyst Michael Gambardella earlier today lowered his estimates and price targets for the steel companies to reflect a "more flattish" steel price environment. The analyst also double downgraded AK Steel (AKS) to Underweight from Overweight and downgraded U.S. Steel (X) to Neutral Overweight. He removed U.S. Steel from his firm's Analyst Focus List. The U.S. steel stocks and steel prices have been under pressure this year, which is largely due to concerns about supply additions planned for the next several years, continued uncertainty surrounding trade, and some softening in demand, Gambardella tells investors in a research note. Further, after a brief rebound, steel and scrap prices are now heading lower, adds the analyst. He kept Overweight ratings on Commercial Metals (CMC), Nucor (NUE), Steel Dynamics (STLD), and Stelco Holdings (STZHF).
09/05/19
BMOC
09/05/19
DOWNGRADE
Target $30
BMOC
Market Perform
Steel Dynamics downgraded to Market Perform from Outperform at BMO Capital
BMO Capital analyst David Gagliano downgraded Steel Dynamics (STLD) to Market Perform from Outperform and lowered his price target for the shares to $30 from $40. The analyst, who still believes shares are undervalued on longer-term fair value estimates, finds the stock's risk/reward more balanced in the near term. There is more downside risk versus upside potential to underlying spot prices into year end, and Steel Dynamics' near-term company-specific catalysts are limited, Gagliano tells investors in a research note. He believes the company, between now and 2022, is more exposed to near-term spot steel pricing volatility. Gagliano coupled the downgrade of Steel Dynamics with an upgrade of Arch Coal (ARCH) to Outperform from Market Perform.
09/05/19
BMOC
09/05/19
DOWNGRADE
BMOC
Market Perform
Steel Dynamics downgraded to Market Perform from Outperform at BMO Capital
08/26/19
08/26/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Foot Locker (FL) downgraded to Neutral from Outperform at Baird and to Neutral from Positive at Susquehanna. 2. Steel Dynamics (STLD) downgraded to Neutral from Buy at Longbow with analyst Christopher Olin saying his confidence in the Steel Mill segment's ability to meet or beat expectations in the second half of 2019 is eroding. 3. Abraxas Petroleum (AXAS) downgraded to Neutral from Buy at Ladenburg with analyst Michael Schmitz saying reduced estimated free cash flow resulting from lower projected commodity prices, combined with uncertainty resulting from the escalation of the trade war, will be additional headwinds for the Exploration and Production group. 4. Elanco (ELAN) downgraded to Neutral from Buy at BofA/Merrill with analyst Michael Ryskin saying while the acquisition of Bayer's (BAYRY) Animal Health business could turn out positive in the longer term, there is too much uncertainty in the near-term, including which parts of the portfolio will be divested due to antitrust issues. 5. Cree (CREE) downgraded to Underweight from Neutral at Piper Jaffray with analyst Harsh Kumar reducing his estimates reducing to reflect broader weakness in the LED market and the impact of Huawei on the Cree's Wolfspeed business. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
IGT International Game
$14.02

(0.00%)

03/12/19
ARGS
03/12/19
NO CHANGE
Target $18
ARGS
Buy
International Game selloff offers 'buying opportunity', says Argus
Argus analyst John Staszak lowered his price target on International Game to $18 from $20 to reflect its "disappointing" Q4 earnings and volatile equipment revenue. The analyst is keeping his Buy rating however, noting that the recent sell-off in the company's stock price represents a buying opportunity given its overall trend of solid free cash flows and efforts to reduce debt, along with the company's steadily growing lottery business and the recent legalization of U.S. sports betting. Staszak adds that casinos "have been slow to upgrade their equipment in recent years" and expects positive impact from the anticipated revitalization of "franchises like Wheel of Fortune".
03/07/19
FBCO
03/07/19
NO CHANGE
FBCO
International Game selloff seems 'overdone,' says Credit Suisse
Credit Suisse analyst Cameron McKnight maintained a Neutral rating and defended the stock after today's selloff, saying while results were "a little soft," they were "no worse than feared." The company also gave guidance slightly below consensus, but it included "$100M of headwinds that were well telegraphed." McKnight said the bottom line is that the stock is now cheap, and longer term the company is "capable of delivering $1.85/share in dividends - which implies a 12% future, potential dividend yield at $15.50/share."
01/09/19
RHCO
01/09/19
UPGRADE
RHCO
Buy
International Game upgraded to Buy from Hold at SunTrust
03/20/19
FBCO
03/20/19
INITIATION
Target $19
FBCO
Neutral
International Game assumed with a Neutral at Credit Suisse
Credit Suisse analyst Ben Combes assumed coverage of International Game with a Neutral rating and $19 price target.
JPM JPMorgan
$116.39

(0.00%)

09/24/19
MSCO
09/24/19
NO CHANGE
MSCO
Large-cap banks aren't gaining deposit market share, says Morgan Stanley
Morgan Stanley analyst Ken Zerbe said he continues to hear the "false narrative" that large-cap banks must be gaining market share due to their superior technology, but he insists they are not and that small and mid-cap banks have consistently gained deposit market share over the last five years. Individual large-cap banks that have had the biggest deposit share gains include Goldman Sachs (GS), Ally Financial (ALLY) and Synchrony Financial (SYF), while mid-cap banks that have delivered the biggest gains in share of total deposits include First Republic (FRC), KeyCorp (KEY) and Huntington (HBAN), Zerbe tells investors. Large-cap banks that have seen the largest declines in their respective individual shares of total deposits include JPMorgan (JPM), Wells Fargo (WFC) and Citigroup (C), while deposit share losers among mid-cap banks include Comerica (CMA), Prosperity Bancshares (PB) and Zions (ZION), said Zerbe.
09/16/19
09/16/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Halliburton (HAL) downgraded to Equal Weight from Overweight at Barclays with analyst J. David Anderson saying he sees "only modest upside" to the shares after revising his estimates lower. 2. Aurora Cannabis (ACB) downgraded to Sell from Hold at Stifel with analyst W. Andrew Carter saying he sees "meaningful downside" from current share levels following the company's "disappointing" Q4 earnings release. 3. HP Inc. (HPQ) downgraded to Neutral from Buy at UBS with analyst John Roy saying he points to downside risk for the company's flat expectations in its printing supplies business amid low visibility and uncertain macro backdrop. Roy further believes that HP's PC margin would decline by more than consensus as the company passes through the component price declines and the sales mix shift away from commercial. 4. Dick's Sporting (DKS) downgraded to Market Perform from Outperform at Wells Fargo with analyst Tom Nikic saying now that Dick's has returned to positive comps and the stock has re-rated, the risk/reward is more evenly balanced. 5. JPMorgan (JPM) downgraded to Neutral from Buy at Buckingham with analyst James Mitchell citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/16/19
BUCK
09/16/19
DOWNGRADE
Target $122
BUCK
Neutral
Buckingham downgrades 'great company' JPMorgan to Neutral on valuation
As previously reported, Buckingham analyst James Mitchell downgraded JPMorgan to Neutral from Buy, calling it a "great company" whose shares have become fairly valued and now trade at nearly a 30% premium on a P/E basis to its peer group. He stills views JPMorgan as an attractive story for long-term holders and believes its "best-in-class" top line growth and returns can continue. Mitchell has a $122 price target on JPMorgan shares.
09/16/19
BUCK
09/16/19
DOWNGRADE
BUCK
Neutral
JPMorgan downgraded to Neutral from Buy at Buckingham
UNH UnitedHealth
$220.32

(0.00%)

10/10/19
RHCO
10/10/19
NO CHANGE
Target $330
RHCO
Hold
SunTrust 'bullish' across healthcare services space ahead of Q3 results
SunTrust analyst David MacDonald says he remains "bullish" across much of the healthcare services space ahead of third quarter results, citing "solid" core trends, "attractive" secular tailwinds, "robust" M&A and "strong" free cash flow. While he expects ongoing intermittent "chop" as industry noise continues to weigh, he views the risk of meaningful structural change as quite low, continues to favor scaled, integrated providers in the ongoing shift towards value and views valuation risk/rewards as increasingly attractive. The analyst tells investors in a research note that he does not necessarily view Q3 results as a meaningful trigger and thinks improved visibility around the election and Democratic primary is key, MacDonald remains bullish on core fundamentals, sees significant inherent sector drivers and says Managed Care remains a favorite fundamental sector. The analyst raised his price target for Anthem (ANTM) to $330 from $290, on Centene (CNC) to $80 from $72, on Cigna (CI) to $260 from $230, on Humana (HUM) to $340 from $310, on Molina (MOH) to $180 from $165, on UnitedHealth (UNH) to $330 from $310, on WellCare (WCG) to $340 from $320, on Ensign Group (ENSG) to $60 from $44 and Tivity Health (TVTY) to $24 from $21.
10/10/19
JEFF
10/10/19
DOWNGRADE
Target $235
JEFF
Hold
Jefferies downgrades UnitedHealth to Hold, cuts Managed Care price targets
Jefferies analyst David Windley downgraded UnitedHealth (UNH) to Hold from Buy with a price target of $235, down from $300. Managed Care sentiment "turned abruptly negative a year ago and has stubbornly remained there," Windley tells investors in a research note. Further, the political risk causing this won't likely abate for at least another nine months, contends the analyst. In addition to the political overhang, he's concerned UnitedHealth's (UNH) commercial enrollment is at risk to Anthem (ANTM). Along with the downgrade of UnitedHealth, Windley cut his price target for Buy-rated Anthem to $299 from $365, for Buy-rated Centene (CNC) to $53 from $76, for Buy-rated Cigna (CI) to $203 from $233, for Buy-rated Humana (HUM) to $322 from $352, for Buy-rated Molina Healthcare (MOH) to $133 from $173 and for Hold-rated WellCare (WCG) to $264 from $302.
10/08/19
CANT
10/08/19
NO CHANGE
Target $310
CANT
Overweight
UnitedHealth pullback on policy noise an opportunity, says Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper says shares of UnitedHealth are attractive at current levels. He reiterates an Overweight rating on the name with a $310 price target ahead of the company's Q3 results on October 15. Optum will continue to be a strong growth driver for UnitedHealth, driven by solid performance across all three of the unit's operating segments, Halper tells investors in a pre-earnings research note. The analyst continue believe sweeping changes to the U.S. healthcare system, which has pressured the stock, are unlikely. Policy noise has created an attractive buying opportunity into UnitedHealth, says Halper.
10/10/19
JEFF
10/10/19
DOWNGRADE
Target $235
JEFF
Hold
UnitedHealth downgraded to Hold from Buy at Jefferies
Jefferies analyst David Windley downgraded UnitedHealth to Hold from Buy with a price target of $235, down from $300.
GS Goldman Sachs
$205.81

(0.00%)

10/14/19
KBWI
10/14/19
NO CHANGE
KBWI
Hard for Goldman, Morgan Stanley to justify E-Trade deal, says Keefe Bruyette
Keefe Bruyette analyst Brian Kleinhanzl looked into whether an acquisition of E-Trade (ETFC) would make sense for Goldman Sachs (GS) or Morgan Stanley (MS) after the electronic brokers reduced their commission rates. The analyst says he could make the strategic rationale for why a broker would buy an e-broker, namely cost savings and customer base expansion. However, ultimately a deal has to make sense financially as well, and it would be hard for Morgan or Goldman to justify on this basis, Kleinhanzl tells investors in a research note. In addition, with both brokers trading near tangible book value, shareholders would prefer buybacks versus an acquisition as a better use of shareholder capital at this point in the cycle, adds the analyst. As such a result, Kleinhanzl sees a deal for E-Trade as unlikely given the financial and capital impacts. He would be surprised if either broker aggressively pursued E-Trade as an acquisition.
09/05/19
ODEN
09/05/19
DOWNGRADE
ODEN
Hold
Goldman Sachs downgraded to Hold from Buy at Odeon Capital
Odeon Capital analyst Richard Bove downgraded Goldman Sachs to Hold from Buy, stating that he respects CEO David Solomon for moving aggressively to fix the bank's problems, but "the task is sizable and apparently it will take more time and more effort to put the company on a sounder course."
10/02/19
ODEN
10/02/19
NO CHANGE
ODEN
Hold
Goldman Sachs 'quite likely' to beat Q3 earnings consensus, says Odeon Capital
Odeon Capital analyst Richard Bove pointed out three reasons that he believes it is "quite likely" that Goldman Sachs will top the Q3 consensus EPS forecast of $5.41. The bank was ranked by Bloomberg as number one in U.S. equity offerings in the quarter, trading activity is likely to be higher on both a sequential and year-over-year basis and Goldman "typically" starts the process of lowering estimated compensation expenses in Q3, said Bove. Bove keeps a Hold rating on Goldman Sachs shares, noting that he thinks Goldman is unlikely to match its Q3 results in Q4.
NVDA Nvidia
$186.51

(0.00%)

10/09/19
PIPR
10/09/19
NO CHANGE
Target $200
PIPR
Overweight
Nvidia's two biggest growth drivers are back, says Piper Jaffray
Piper Jaffray analyst Harsh Kumar believes Nvidia's (NVDA) two biggest growth drivers, namely gaming and data center, are back. Following a round of channel checks, the analyst says Nvidia is one of the best positioned semiconductor companies from a "company-specific catalyst perspective." Gaming, which represents around half of the company's revenue, appears to have settled following the GPU inventory correction, and the segment is setup for a seasonally strong second half of 2019, Kumar tells investors in a research note. In addition, the analyst is convinced Nvidia's data center business appears to have stabilized, and he sees growth in the segment moving forward. Further, Kumar thinks the Mellanox (MLNX) acquisition is on track to close by the end of calendar 2019. Lastly, based on Piper's teen survey results, the analyst believes video game interest remains high among U.S. teens. He keeps an Overweight rating on Nvidia with a $200 price target. The stock closed Tuesday down $7.10 to $177.23.
10/07/19
RBCM
10/07/19
NO CHANGE
Target $217
RBCM
Outperform
Nvidia price target raised to $217 from $190 at RBC Capital
RBC Capital analyst Mitch Steves raised his price target on Nvidia to $217 and kept his Outperform rating, saying he expects the stock to be the best performing large-cap name in his coverage universe within the next 6-9 months. The analyst cites indications of a pick-up in the gaming demand, which he sees as tracking ahead of the company's plans. Steves also believes that Nvidia's Data Center should recover in Q4 thanks to the product refresh announcement expected in the quarter, further supporting his forecast of expanding gross margins.
10/07/19
EVER
10/07/19
NO CHANGE
Target $225
EVER
Outperform
Nvidia price target raised to $225 from $185 at Evercore ISI
Evercore ISI analyst C.J. Muse said in a note before the open that he thinks it is understandable that investors have taken a cautious view on the future growth of Nvidia's Gaming franchise, though he sees a potential recovery coming in the second half and momentum continuing into 2020 and beyond in that part of the company's business. Muse sees at least a 15% compound annual growth rate for Gaming into 2022, led by Notebook Gaming growth, even without giving credit for any contributions from Cloud gaming via wins at CSPs and GeForce Alliance, which could be a source of added upside. The analyst, who now predicts Nvidia EPS approaching $9.25 in the 2021 timeframe, reiterated his Outperform rating on the shares and raised his price target to $225 from $185. Nvidia, which also saw its price target raised to $217 from $190 at RBC Capital this morning, is up 3% to $187.44 in early trading.
10/15/19
BOFA
10/15/19
NO CHANGE
Target $250
BOFA
Buy
Nvidia price target raised to $250 from $225 at BofA/Merrill
BofA Merrill Lynch analyst Vivek Arya raised his price target on Nvidia shares to $250 from $225 as he believes the company's data center growth will soon benefit from "the next-big AI landmark," namely natural language processing, or "conversational AI." The ability to accurately listen, understand, speak and contextualize human speech needs compute requirements 100 times that of today's dominant image/video classifier AI machines, said Arya, who sees Nvidia being "in prime position" to benefit from this shift given its portfolio of hardware and software and its developer ecosystem. Arya keeps a Buy rating on Nvidia, which he continues to identify as his top large-cap pick.
HYG iShares iBoxx $ High Yield Corporate Bond
$86.83

(0.00%)

C Citi
$70.28

(0.00%)

07/26/19
07/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Goldman Sachs (GS) and Citi (C) upgraded to Outperform from Market Perform at Keefe Bruyette. 2. Ambev (ABEV) upgraded to Neutral from Underweight at JPMorgan with analyst Lucas Ferreira saying the post-earnings share rally shows that investors are chasing good growth stories to play Brazil's economic recovery. 3. West Pharmaceutical (WST) upgraded to Neutral from Underperform at BofA/Merrill with analyst Derik de Bruin saying that over the course of the first half, the company addressed his prior concerns around organic revenue growth and product mix trends while also boosting its operating margins and generating higher free cash flows. 4. Union Pacific (UNP) upgraded to Overweight from Neutral at Atlantic Equities, while CSX (CSX) was upgraded to Neutral from Underweight. 5. Hasbro (HAS) upgraded to Buy from Hold at Argus with analyst John Staszak citing the company's dominant position with a range of "strong" brands as well as in the big-screen business. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/10/19
UBSW
09/10/19
DOWNGRADE
Target $49
UBSW
Neutral
Wells Fargo downgraded to Neutral from Buy at UBS
UBS analyst Saul Martinez downgraded Wells Fargo (WFC) to Neutral and lowered his price target on the stock to $49 from $51. The analyst attributes the rating change to his reduced estimates for earnings and lower net interest income along with the continued uncertainty and low visibility around the progress in the management's efficiency improvements. Martinez also cites Wells Fargo's relative valuation, with shares trading at 11.3-times expected FY20 earnings - a premium to JP Morgan's (JPM) 10.8-times, Bank of America's (BAC) 9.2-times, and Citigroup's (C) 7.9-times.
09/06/19
BOFA
09/06/19
NO CHANGE
BOFA
BofA/Merrill sees Citi, Citizens BB&T risk/reward as 'compelling'
BofA Merrill Lynch analyst Erika Najarian said she does not believe bank stocks are pricing in a recession, though they are "bearing the brunt of cycle concerns." Bank stocks could be at a near-term bottom, said Najarian, who sees compelling risk/rewards for shares of Citi (C), Citizens Financial (CFG) and BB&T (BBT) even when taking into account theoretical fair value in a recession. Even in the case of a recession, banks have materially improved underwriting since the financial crisis and she estimates an average 46% EPS hit in a downturn but only a 5% hit in tangible book value versus consensus 2020 forecasts, Najarian tells investors.
WLL Whiting Petroleum
$7.26

(0.00%)

10/15/19
WOLF
10/15/19
DOWNGRADE
Target $8
WOLF
Underperform
Whiting Petroleum downgraded to Underperform from Peer Perform at Wolfe Research
Wolfe Research analyst Josh Silverstein downgraded Whiting Petroleum to Underperform from Peer Perform with a price target of $8, down from $12. The analyst sees increased financial risk given Whiting's inability to generate free cash flow and growth with WTI at $50/bbl and expectations for the 2020 outlook to be below Street expectations.
10/10/19
GHSC
10/10/19
DOWNGRADE
GHSC
Neutral
Seaport Global cuts Whiting Petroleum to Neutral among 13 E&P downgrades
As previously reported, Seaport Global analyst Mike Kelly downgraded Whiting Petroleum to Neutral from Buy. The rating change was among 13 downgrades made in the E&P sector by Kelly, who contends that "the 2020 oil macro set up is a mess." On Whiting specifically, he said liquidity has become the focus as the company deals with debt maturities and as leverage creeps up. The 2020 outlook "looks uninspiring for an equity holder" if oil is at $51.50, concludes Kelly.
10/04/19
10/04/19
DOWNGRADE

Underperform
Whiting Petroleum cut to Underperform at Credit Suisse on looming debt concerns
As previously reported, Credit Suisse analyst Betty Jiang downgraded Whiting Petroleum and lowered her price target to $5 from $11. The analyst contends that the stock has underperformed in 2019 not only because of expectations of softer energy prices but also in response to "significant downward revisions of asset productivity expectations." Jiang believes that more downside is yet to come amid an uncertain macro outlook, no free cash flow "at strip prices", a levered balance sheet of over 3-times, and looming debt maturities.
10/10/19
GHSC
10/10/19
DOWNGRADE
GHSC
Neutral
Whiting Petroleum downgraded to Neutral from Buy at Seaport Global
SCHW Charles Schwab
$37.74

(0.00%)

10/09/19
DBAB
10/09/19
NO CHANGE
DBAB
Hold
Deutsche sees 'major' M&A as potential path for E-Trade, Ameritrade
Charles Schwab's (SCHW) move to cut trade commissions to zero is likely to spur business model changes at TD Ameritrade (AMTD) and E-Trade Financial (ETFC), Deutsche Bank analyst Brian Bedell tells investors in a research note. Instead of managing "persistent" revenue declines, management teams should seek to leverage their strong operating platforms and loyal customer base into a more diversified retail financial service offering that includes online banking, digital wealth management and investment advisory, argues the analyst. This may require "major" M&A for E-Trade and Ameritrade, while Schwab can likely augment its wider range of offerings organically or via smaller bolt on deals, says Bedell. He still views Ameritrade as the "most efficient acquirer" of E-Trade, but finds it no longer clear that the combination "would create a broad enough financial services offering for the new revenue paradigm." One alternative idea could be an E-Trade combination with a digital banking and wealth management platform, says the analyst, who analyzed a potential merger with Goldman Sachs (GS). Bedell also wonders if Ameritrade will eventually explore strategic alternatives or if 43% owner TD Bank (TD) will eventually seek to acquire a much larger controlling stake in the company.
10/09/19
JEFF
10/09/19
NO CHANGE
Target $43
JEFF
Buy
Jefferies says Schwab best positioned discount broker after commission cuts
Jefferies analyst Daniel Fannon said following last week's commission cut announcements that he views Charles Schwab (SCHW) as the best positioned discount broker to capitalize on trends in the industry toward fee-based advice and advisors going independent. Interest rates will "push around near-term profitability," but he believes Schwab's net new asset growth is poised to remain industry-leading, Fannon said. Among publicly traded companies in the space, Fannon still views E-Trade (ETFC) as the most likely M&A candidate, he added. Given the recent commission cuts, he lowered his price target on Schwab shares to $43 from $49, lowered his price target on E-Trade to $44 from $54 and cut his price target on TD Ameritrade (AMTD) to $36 from $55. Fannon has Buy ratings on the first two stocks mentioned and a Hold rating on TD Ameritrade.
10/14/19
SBSH
10/14/19
NO CHANGE
SBSH
Citi opens '30-Day Negative Catalyst Watch' on Waddell & Reed
Citi analyst William Katz opened a "30-Day Negative Catalyst Watch" for Sell-rated Waddell & Reed (WDR) and initiated a "90-Day Positive Catalyst Watch" on Buy-rated Carlyle Group (CG). He also initiated a "Persistent Existentialism" pair trade, or overweight Charles Schwab (SCHW) and underweight TD Ameritrade (AMTD), a stock he downgraded this morning to Sell from Neutral. Into the Q3 earnings season, the analyst lowered his 12-month price targets for the Brokers and Asset Managers to reflect a combination of lower target multiples and reduced earnings prospects.
10/03/19
10/03/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Market Perform from Outperform at JMP Securities with analyst Joseph Osha saying that while the figures were not "significantly far off" from consensus, delivery unit growth was in low-single-digits with no indications of operational issues. 2. Charles Schwab (SCHW) and E-Trade (ETFC) downgraded to Market Perform from Outperform at Wells Fargo while TD Ameritrade (AMTD) was downgraded to Underperform from Outperform. 3. Teligent (TLGT) downgraded to Market Perform from Outperform at Raymond James with analyst Elliot Wilbur citing the announcement of a strategic review of assets that are non-core to the company's long-term strategy. 4. Insulet (PODD) downgraded to Neutral from Buy at Guggenheim with analyst Chris Pasquale saying while he continues to see the company being competitively well positioned, he now sees the risk/reward as less attractive. 5. Delta Air Lines (DAL) downgraded to Neutral from Buy at Buckingham. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

CWK

Cushman & Wakefield

$19.10

0.1 (0.53%)

17:48
11/15/19
11/15
17:48
11/15/19
17:48
Hot Stocks
Cushman & Wakefield CEO sells 84.6K share of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

LMT

Lockheed Martin

$393.52

3.305 (0.85%)

17:39
11/15/19
11/15
17:39
11/15/19
17:39
Hot Stocks
Lockheed Martin awarded maximum $3.33B Air Force contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESCA

Escalade

$10.90

-0.09 (-0.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Escalade CEO Fetherman to retire »

Escalade announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$12.96

0.1 (0.78%)

, ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Eldorado, Caesars stockholders approve Eldorado acquisition of Caesars »

Eldorado Resorts (ERI)…

CZR

Caesars

$12.96

0.1 (0.78%)

ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

EGRX

Eagle Pharmaceuticals

$57.24

0.55 (0.97%)

17:15
11/15/19
11/15
17:15
11/15/19
17:15
Syndicate
Breaking Syndicate news story on Eagle Pharmaceuticals »

Eagle Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FN

Fabrinet

$60.82

0.84 (1.40%)

17:11
11/15/19
11/15
17:11
11/15/19
17:11
Hot Stocks
Fabrinet President Gill sells 12.9K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

TEUM

Pareteum

$0.38

-0.0209 (-5.21%)

17:05
11/15/19
11/15
17:05
11/15/19
17:05
Hot Stocks
Pareteum receives noncompliance notice from Nasdaq »

Pareteum announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEXO

Hexo

$1.78

-0.1 (-5.32%)

17:00
11/15/19
11/15
17:00
11/15/19
17:00
Hot Stocks
Hexo was cannabis was being grown in unlicensed space at Niagara site »

HEXO Corp provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$220.84

2.29 (1.05%)

, CELG

Celgene

$110.02

-0.01 (-0.01%)

16:57
11/15/19
11/15
16:57
11/15/19
16:57
Hot Stocks
Bristol-Myers gets FTC clearance for Celgene acquisition »

Bristol-Myers Squibb…

AMGN

Amgen

$220.84

2.29 (1.05%)

CELG

Celgene

$110.02

-0.01 (-0.01%)

BMY

Bristol-Myers

$58.61

0.11 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 04

    Dec

  • 07

    Dec

  • 25

    Mar

  • 04

    Apr

RAVE

Rave Restaurant

$1.44

-0.79 (-35.43%)

16:47
11/15/19
11/15
16:47
11/15/19
16:47
Hot Stocks
BBRC Asset Management reports 6.6% passive stake in Rave Restaurant »

BBRC Asset Management …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHAP

Chaparral Energy

$0.89

-0.0521 (-5.52%)

16:46
11/15/19
11/15
16:46
11/15/19
16:46
Hot Stocks
Chaparral Energy receives continued listing standard notice from NYSE »

Chaparral Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:45
11/15/19
11/15
16:45
11/15/19
16:45
General news
Breaking General news story  »

San Francisco Federal…

16:45
11/15/19
11/15
16:45
11/15/19
16:45
General news
Breaking General news story  »

San Francisco Federal…

CI

Cigna

$196.08

6.41 (3.38%)

, CNC

Centene

$57.57

2.91 (5.32%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks closed out the…

CI

Cigna

$196.08

6.41 (3.38%)

CNC

Centene

$57.57

2.91 (5.32%)

CVS

CVS Health

$74.27

1.34 (1.84%)

HUM

Humana

$335.43

17.48 (5.50%)

UNH

UnitedHealth

$269.44

13.68 (5.35%)

WCG

WellCare

$312.01

10.155 (3.36%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$129.60

7.3 (5.97%)

ANTM

Anthem

$298.18

16.14 (5.72%)

HCA

HCA Healthcare

$137.98

3.51 (2.61%)

CYH

Community Health

$3.12

0.25 (8.71%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$144.30

3.13 (2.22%)

NVDA

Nvidia

$204.12

-5.76 (-2.74%)

AMZN

Amazon.com

$1,739.33

-15.38 (-0.88%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

UAA

Under Armour

$17.78

0.65 (3.79%)

UA

Under Armour

$15.97

0.41 (2.64%)

AMRN

Amarin

$23.99

2.5 (11.63%)

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

GOOG

Alphabet

$1,334.01

21.82 (1.66%)

GOOGL

Alphabet Class A

$1,333.33

23.54 (1.80%)

ORCL

Oracle

$56.43

0.33 (0.59%)

RH

RH

$188.73

13.535 (7.73%)

QGEN

Qiagen

$40.56

3.255 (8.73%)

FTCH

Farfetch

$9.66

2.17 (28.97%)

THC

Tenet

$30.55

1.08 (3.66%)

TORC

resTORbio

$1.10

-6.83 (-86.13%)

ACB

Aurora Cannabis

$2.72

-0.57 (-17.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 22

    Nov

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 13

    Dec

  • 28

    Dec

  • 06

    Jan

  • 21

    Jan

  • 06

    Feb

NYT

New York Times

$31.60

0.44 (1.41%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
Hot Stocks
New York Times CEO sells 66,000 class A common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

WEX

Wex

$200.52

4.61 (2.35%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
Hot Stocks
Wex director Morris sells 3K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBLI

Cleveland BioLabs

$0.59

-0.0444 (-6.97%)

16:39
11/15/19
11/15
16:39
11/15/19
16:39
Hot Stocks
Cleveland BioLabs CEO resigns effective December 13th »

In a regulatory 8-K…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGC

LogicBio Therapeutics

$9.29

-0.04 (-0.43%)

16:38
11/15/19
11/15
16:38
11/15/19
16:38
Syndicate
Breaking Syndicate news story on LogicBio Therapeutics »

LogicBio Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTBI

HomeTrust

$25.99

-0.31 (-1.18%)

16:38
11/15/19
11/15
16:38
11/15/19
16:38
Hot Stocks
HomeTrust raises quarterly dividend 17% to 7c per share »

HomeTrust Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

FR

First Industrial Realty

$42.05

-0.03 (-0.07%)

16:36
11/15/19
11/15
16:36
11/15/19
16:36
Hot Stocks
First Industrial Realty director sells 12K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSI

United Bankshares

$39.51

-0.19 (-0.48%)

16:31
11/15/19
11/15
16:31
11/15/19
16:31
Hot Stocks
United Bankshares declares Q4 dividend of 35c per share »

United Bankshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
11/15/19
11/15
16:30
11/15/19
16:30
Options
Preliminary option volume of 24.0M today »

Preliminary option volume…

16:25
11/15/19
11/15
16:25
11/15/19
16:25
Conference/Events
Federal Reserve Bank of San Francisco participates in a discussion »

San Francisco Federal…

GNLN

Greenlane

$3.36

-0.05 (-1.47%)

16:23
11/15/19
11/15
16:23
11/15/19
16:23
Hot Stocks
Greenlane CEO buys 56.4K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AJG

Arthur J. Gallagher

$91.89

-0.42 (-0.45%)

16:20
11/15/19
11/15
16:20
11/15/19
16:20
Syndicate
Breaking Syndicate news story on Arthur J. Gallagher »

Arthur J. Gallagher files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.